Q-Symbio

Q-Symbio is a clinical trial that was conducted to evaluate the effects of the dietary supplement Coenzyme Q10 (CoQ10) on patients with Heart Failure. The trial was a multicenter, randomized, double-blind, placebo-controlled study that took place over a period of two years.

Overview

The Q-Symbio trial was designed to assess the long-term effects of CoQ10 supplementation on morbidity and mortality in chronic heart failure patients. The trial was conducted across several countries, including Denmark, Slovakia, Poland, Hungary, India, Malaysia, and Australia. The study was named after the supplement used in the trial, Q-Symbio, which is a formulation of CoQ10.

Methodology

The trial involved 420 patients with moderate to severe heart failure. The patients were randomly assigned to receive either 300 mg of CoQ10 per day or a placebo, in addition to their standard heart failure treatment. The primary endpoint of the trial was time to first major adverse cardiovascular event (MACE), which included unplanned hospitalization due to worsening of heart failure, cardiovascular death, urgent cardiac transplantation, and mechanical circulatory support.

Results

The results of the Q-Symbio trial showed that supplementation with CoQ10 significantly reduced the risk of MACE in chronic heart failure patients. The study also found that CoQ10 improved symptoms and functional status of heart failure patients.

Significance

The Q-Symbio trial is significant because it provides evidence for the potential benefits of CoQ10 supplementation in heart failure patients. The results of the trial suggest that CoQ10 could be a safe and effective adjunctive treatment for heart failure.

See Also

• Coenzyme Q10
• Heart Failure
• Clinical Trial
• Dietary Supplement